Lipocine Inc.
Lipocine is a biopharmaceutical company headquartered in Salt Lake City, Utah, focused on developing oral delivery products for drugs that are difficult to deliver by mouth. Its proprietary technology uses lipid-based formulations to improve drug absorption. The company’s portfolio includes candidates for neurological and psychiatric disorders, liver disease, and hormone supplementation for men and women. Its clinical pipeline includes LPCN 1154 for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2101 for epilepsy, and LPCN 2203 for essential tremor. Lipocine’s commercial product is TLANDO, an oral testosterone replacement therapy approved by the FDA in March 2022. It licenses commercialization rights to partners in the United States and Canada, South Korea, the Gulf Cooperation Council countries, and Brazil, and supplies product to some licensees. It earns money through license fees, milestone payments, royalties on sales, and product supply. The company also licenses LPCN 1111, a potential once-daily oral testosterone replacement therapy candidate, in the United States and Canada.
No enriched coverage for $LPCN in the last 7 days.
Lipocine Inc (LPCN) shares rose 30% premarket after Health Canada approved its oral testosterone drug TLANDO, marketed by Verity Pharmaceuticals. TLANDO offers an alternative to injections and gels. Verity Pharma plans a 2026 Canadian launch. Over 700,000 testosterone prescriptions are written annually in Canada, with injections holding the largest share.
Lipocine Inc. (NASDAQ: LPCN) shares rose 30.95% after initiating its BLOOM Phase 3 trial for LPCN 1154, a treatment for severe postpartum depression. The company reported $1.9M in revenue and $23.3M in cash. H.C. Wainwright maintained a Neutral rating with a $4 price target, expecting data in 2027. Traders are watching for catalysts like updates or financing moves.
Lipocine announced Health Canada approval for TLANDO, an oral testosterone replacement therapy for adult males. Verity Pharma, Lipocine's licensee, plans to launch TLANDO in Canada by end-2026. The drug offers a fixed-dose option, potentially improving convenience and compliance. Over 700,000 TRT prescriptions are written annually in Canada, indicating a significant market opportunity.
Recent LPCN coverage spans regulation, insider activity and corporate actions.
In the last 30 days, LPCN insiders filed 3 SEC Form 4 transactions — 3 purchases ($82K) and no sales. The most active reporter was Higuchi John W. with 3 filings.
Approval unlocks Canadian market and validates US FDA approval, likely boosting sales and share price.
The trial start provides a fresh catalyst that has already driven a sharp price jump and is likely to sustain buying pressure.
Approval opens a sizable Canadian TRT market, likely boosting Lipocine's revenue outlook.
Approval opens a new market for TLANDO, likely boosting Lipocine's revenue outlook.
Small insider purchase may signal modest confidence but size is negligible for price.
AlphAI scores every news story that mentions LPCN with an AI model for sentiment and relevance, and aggregates insider trades from Lipocine Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Lipocine Inc (LPCN) shares rose 30% premarket after Health Canada approved its oral testosterone drug TLANDO, marketed by Verity Pharmaceuticals. TLANDO offers an alternative to injections and gels. Verity Pharma plans a 2026 Canadian launch. Over 700,000 testosterone prescriptions are written annually in Canada, with injections holding the largest share.
2 min readLipocine Inc. (NASDAQ: LPCN) shares rose 30.95% after initiating its BLOOM Phase 3 trial for LPCN 1154, a treatment for severe postpartum depression. The company reported $1.9M in revenue and $23.3M in cash. H.C. Wainwright maintained a Neutral rating with a $4 price target, expecting data in 2027. Traders are watching for catalysts like updates or financing moves.
2 min readLipocine announced Health Canada approval for TLANDO, an oral testosterone replacement therapy for adult males. Verity Pharma, Lipocine's licensee, plans to launch TLANDO in Canada by end-2026. The drug offers a fixed-dose option, potentially improving convenience and compliance. Over 700,000 TRT prescriptions are written annually in Canada, indicating a significant market opportunity.
1 min readLipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Lipocine Announces Health Canada Approval of TLANDO ® for Testosterone Replacement Therapy SALT LAKE CITY, October 7, 2026 -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that,
2 min readHiguchi John W. purchased 25,007 shares of Lipocine Inc. (LPCN) at an average of $2.20 ($2.15–$2.23) across 2 trades over 2026-09-29 to 2026-09-30.
1 min readBerkshire Hathaway increased its stake in Lennar (LEN) by $53.8M, buying shares at $79.98-$81.96. Other notable insider activity includes Conifer Management's $66.3M purchase of Group 1 Automotive (GPI) shares, and CEO Michael Hsing's $40.3M sale of Monolithic Power Systems (MPWR) stock. InvestingPro analysis suggests undervaluation for LEN, GPI, and others, while MPWR is deemed overvalued.
3 min readHiguchi John W. purchased 12,561 shares of Lipocine Inc. (LPCN) at $2.16 on 2026-09-28.
1 min readLipocine Inc. (LPCN) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 8, 2026, Lipocine Inc. (the “Company”) and A.G.P./Alliance Global Partners (the “Sales Agent”) agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent (th
1 min readLipocine Inc. (LPCN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 SALT LAKE CITY, August 4, 2026 — Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results
6 min readLipocine Inc. (LPCN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Lipocine Inc. Lipocine Appoints Michael J. Grissinger to Board of Directors SALT LAKE CITY, August 3, 2026 — Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delive
2 min read
